Mark H. O'Hara

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Attending, Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-306
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215)360-0735
Fax: (215)662-4646
Education:
BS (Biology - Molecular Genetics)
University of Rochester, 2004.
MD (Medicine)
Stony Brook School of Medicine, 2008.
Permanent link
 

Description of Itmat Expertise

Immunotherapy in cancer
Targeted therapy in cancer
Pancreatic cancer
Colon cancer
Cholangiocarcinoma
Neuroendocrine tumor
Phase 1 clinical trials

Description of Research Expertise

Pancreatic cancer, colorectal cancer, GI cancers, Phase 1, CAR T cell therapy

Selected Publications

Shabason JE, Chen J, Apisarnthanarax S, Damjanov N, Giantonio B, Loaiza-Bonilla A, O'Dwyer PJ, O'Hara M, Reiss KA, Teitelbaum U, Wissel P, Drebin JA, Vollmer C, Kochman M, Mick R, Vergara N, Jhala N, Doucette A, Lukens JN, Plastaras JP, Metz JM, Ben-Josef E.: A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Cancer Chemother Pharmacol. Jan 23 2018 Notes: doi: 10.1007/s00280-018-3519-6 Epub ahead of print.

Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer. : Karasic TB, O’Hara MH, Teitelbaum UR, Damjanov N, Giantonio BJ, d’Entremont TS, Gallagher M, Zhang PJ, O’Dwyer PJ. J Clin Oncol, (4S_suppl), 68 36, 2018 Notes: "Poster Presentation"

A single arm phase II study of rucapariob maintenance in patients with advanced pancreatic adenocarcinoma and a known deleterious BRCA1, BRCA2 or PALB2 mutation who have achieved stability on platinum therapy. : Reiss KA, Maxwell KN, Nathanson K, Teitelbaum UR, O’Hara MH, O’Dwyer PJ, Schneider C, Carpenter EL, Mick R, Domcheck SM. J Clin Oncol 36(4S_suppl), TPS531 2018 Notes: "Poster Presentation"

Reiss KA, Ben-Josef E, Damjanov N, Hoteit M, O’Hara MH, Karasic TB, Teitelbaum UR, Schneider C, O’Dwyer PJ, Carpenter EL, Mick R, Vonderheide RH. : A pilot study of galunisertib (LY2157299) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 36(4S_suppl), TPS528 2018 Notes: "Poster Presentation"

Ko J, Bhagwat N, Yee SS, Ortiz N, Sahmoud A, Black T, Aiello NM, McKenzie L, O’Hara M, Redlinger C, Romeo J Carpenter EL, Stanger BZ, Issadore D: Combining machine learning and nanofluidic technology to diagnose pancreatic cancer using exosomes. ACS Nano 11(11): 11182-11193, Nov 2017.

O’Hara MH, Mick R, Lyman J, Xu J, Hosseini M, LaVallee T, Gherardini PF, Vance B, Trifan O, Dugan U, Shalabi A, Ibrahima R, Vonderheide RH. : A phase Ib/2 study of CD40 agonistic monoclonal antibody (APX005M) together with gemcitabine and nab-paclitaxel with or without nivolumab in untreated metastatic pancreatic adenocarcinoma patients. Society for Immunotherapy of Cancer (SITC), National Harbor, MD Nov 8-12 2017 Notes: "Oral Presentation"

Ko J, Bhagwat N, Yee SS, Black T, Redlinger C, Romeo J, O’Hara M, Raj A, Carpenter EL, Stanger BZ, Issadore D: A magenetic micropore chip for rapid (<1 hour) unbiased circulating tumor cell isolation and in situ RNA analysis. Lab Chip 17(18): 3086-3096, Sep 2017.

O’Hara MH, Stashwick C, Plesa G, Tanyi JL: Overcoming barriers of CAR T cell therapy in patients with mesothelin-expressing cancers. Immunotherapy 9(9): 767-780, Aug 2017.

O'Hara MH, Loaiza-Bonilla A, Redlinger M, Damjanov N, Teitelbaum UR, Vasilevskaya I, Rosen MA, Heitjan DF, Amaravadi RK, O'Dwyer PJ: Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer. American Society of Clinical Oncology Annual Conference, Chicago, IL Jun 2017 Notes: "Poster Presentation"

Flynn JP, O’Hara MH, Gandhi SJ. : Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e. CART). Translational Lung Cancer Research 6(2): 159-168, Apr 2017.

back to top
Last updated: 03/28/2018
The Trustees of the University of Pennsylvania